Karyopharm Therapeutics | Market Exclusive

Home Tags Karyopharm Therapeutics

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Karyopharm Therapeutics (NASDAQ:KPTI)

ME Staff - March 21, 2018 0

Analyst Activity – JPMorgan Chase & Co. Raises Its Price Target...

ME Staff - March 16, 2018 0

Analyst Activity – Canaccord Genuity Raises Its Price Target On Karyopharm...

ME Staff - March 12, 2018 0

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

December 9, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

November 24, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

November 18, 2024

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.

Tag: Karyopharm Therapeutics

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Karyopharm Therapeutics (NASDAQ:KPTI)

Analyst Activity – JPMorgan Chase & Co. Raises Its Price Target...

Analyst Activity – Canaccord Genuity Raises Its Price Target On Karyopharm...

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

POPULAR POSTS

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

POPULAR CATEGORY